1,869 results on '"Freeman, Gordon J."'
Search Results
202. The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018
203. Regulation of HHLA2 expression in kidney cancer and myeloid cells.
204. PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors.
205. Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD‐L1) expression in colorectal carcinoma.
206. mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection
207. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
208. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
209. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
210. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
211. Enterohepatic Shunt-Driven Cholemia Predisposes to Liver Cancer
212. Immuno-Genetic Changes Underlie Response to Immune Checkpoint Blockade Therapy in Richter's Syndrome Mouse Models
213. Immunoregulatory effects of RGMb in gut inflammation
214. Preclinical models for development of immune–oncology therapies
215. Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function
216. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
217. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
218. PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques
219. An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
220. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
221. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells
222. Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
223. Novel Antimurine Thyroid-Stimulating Hormone Receptor Monoclonal Antibodies.
224. PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity.
225. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance.
226. PI3Kβ controls immune evasion in PTEN-deficient breast tumours.
227. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
228. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
229. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma
230. Abstract LB098: Integrative approaches to modulate antigen presentation and boost cancer immune response
231. A comparison of monoclonal antibodies against murine PD-1 and PD-L1
232. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality
233. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
234. Strength of PD-1 signaling differentially affects T-cell effector functions
235. The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings
236. An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
237. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
238. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
239. Adhesion and Costimulatory Molecules
240. Binding of Hepatitis A Virus to Its Cellular Receptor 1 Inhibits T-Regulatory Cell Functions in Humans
241. Author Correction: Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
242. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
243. Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
244. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy
245. The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings
246. Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model
247. Low Dose IL-2 Therapy in Patients with Chronic Gvhd Induces PD-1+treg That Are Highly Activated, Immune Suppressive, and Proapoptotic
248. Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer
249. Soluble PD-L1 as an early marker of progressive disease on nivolumab
250. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.